Publications by authors named "C Reading"
Background: Alzheimer's disease (AD) is a progressive, multifactorial, neurodegenerative disorder affecting >6 million Americans. Chronic, low-grade neuroinflammation, and insulin resistance may drive AD pathogenesis. We explored the neurophysiological and neuropsychological effects of NE3107, an oral, anti-inflammatory, insulin-sensitizing molecule, in AD.
View Article and Find Full Text PDFObjective: Results of ethanol ablation (EA) for controlling neck nodal metastases (NNM) in adult patients with papillary thyroid carcinoma (APTC) beyond 6 months have rarely been reported. We now describe outcome results in controlling 71 NNM in 40 node-positive stage I APTC patients followed for 66 to 269 months.
Methods: All 40 patients were managed with bilateral thyroidectomy and radioiodine therapy and followed with neck ultrasound (US) for >48 months after EA.
Aging and age-related diseases are associated with cellular stress, metabolic imbalance, oxidative stress, and neuroinflammation, accompanied by cognitive impairment. Lifestyle factors such as diet, sleep fragmentation, and stress can potentiate damaging cellular cascades and lead to an acceleration of brain aging and cognitive impairment. High-fat diet (HFD) has been associated with obesity, metabolic disorders like diabetes, and cardiovascular disease.
View Article and Find Full Text PDFArticle Synopsis
- Childhood papillary thyroid carcinoma (CPTC) often recurs in neck nodal metastases (NNM) despite typical treatments, with a 33% recurrence rate even after surgery and radioiodine treatment.
- This study examined the long-term effects of ethanol ablation (EA) in 14 CPTC patients, showing significant shrinkage (average 87%) of NNM after the procedure with no complications.
- The findings suggest that EA is a safe and effective outpatient treatment option for patients with limited NNM who prefer to avoid further surgery or invasive monitoring.
Article Synopsis
- Recent research highlights the significant roles of inflammation and insulin resistance in neurodegenerative diseases like Alzheimer's.
- NE3107 is a promising new oral medication that targets inflammation by selectively inhibiting specific pathways without disrupting their beneficial functions.
- The upcoming Phase III clinical trial (NM101) will test the safety and effectiveness of NE3107 on 316 elderly patients with mild-to-moderate Alzheimer's over 30 weeks, comparing it to a placebo.